120,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Boxer Capital Management LLC

Boxer Capital Management LLC acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $10,188,000. Abivax accounts for 3.2% of Boxer Capital Management LLC’s portfolio, making the stock its 11th largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares in the last quarter. Millennium Management LLC raised its position in shares of Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after purchasing an additional 56,235 shares during the last quarter. Woodline Partners LP lifted its stake in Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after buying an additional 153,788 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Abivax in the 2nd quarter valued at about $139,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Stock Performance

Shares of Abivax stock opened at $115.50 on Friday. The business’s 50 day moving average price is $118.99 and its 200 day moving average price is $108.89. The company has a market cap of $9.13 billion, a price-to-earnings ratio of -27.63 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. On average, research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Guggenheim reiterated a “buy” rating and set a $175.00 price objective on shares of Abivax in a research note on Thursday, December 18th. Oppenheimer set a $131.00 target price on Abivax in a research report on Thursday, January 8th. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Wedbush assumed coverage on Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective for the company. Finally, Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $134.75.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.